1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. News
  7. Summary
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Real-time Estimate Tradegate  -  05/20 11:36:21 am EDT
1.065 EUR   +0.47%
05/19TRANSCRIPT : Biofrontera AG, Q1 2022 Earnings Call, May 19, 2022
CI
05/17Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/13Earnings Flash (BFRI) BIOFRONTERA Posts Q1 Revenue $9.8M, vs. Street Est of $9.83M
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biofrontera AG Reaffirms Earnings Guidance for Fiscal Year 2021

11/17/2021 | 05:00pm EDT

Biofrontera AG announced that performance in the first nine months of 2021 was in line with the Management Board's expectations. The Management Board therefore maintains its guidance for the fiscal year 2021 published on April 12, 2021 in its entirety. Accordingly, the Management Board expects annual revenues between EUR 25 and 32 million as well as EBITDA loss between EUR 11 and 14 million and EBIT loss between EUR 13 and 16 million.


© S&P Capital IQ 2021
All news about BIOFRONTERA AG
05/19TRANSCRIPT : Biofrontera AG, Q1 2022 Earnings Call, May 19, 2022
CI
05/17Biofrontera AG Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/13Earnings Flash (BFRI) BIOFRONTERA Posts Q1 Revenue $9.8M, vs. Street Est of $9.83M
MT
05/02TRANSCRIPT : Biofrontera AG, 2021 Earnings Call, May 02, 2022
CI
04/30Biofrontera AG Reports Earnings Results for the Full Year Ended December 31, 2021
CI
04/30PTA-NEWS : Biofrontera AG: Biofrontera reports results for the fiscal year 2021
PU
04/29Biofrontera AG Provides Earnings Guidance for the Year 2022
CI
04/28PTA-NEWS : Biofrontera AG: Biofrontera shifts the publication of the Annual Report 2021 to..
PU
04/14PTA-NEWS : Biofrontera AG: Biofrontera announces conference call to be held on April 29, 2..
PU
04/13Top Midday Gainers
MT
More news
Financials
Sales 2022 35,7 M 37,7 M 37,7 M
Net income 2022 -1,00 M -1,05 M -1,05 M
Net Debt 2022 - - -
P/E ratio 2022 -53,0x
Yield 2022 -
Capitalization 60,1 M 63,4 M 63,4 M
Capi. / Sales 2022 1,68x
Capi. / Sales 2023 1,73x
Nbr of Employees 99
Free-Float 46,4%
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,06 €
Average target price 3,50 €
Spread / Average Target 230%
EPS Revisions
Managers and Directors
Ludwig Lutter Chief Financial Officer
Wilhelm Konrad Zours Chairman-Supervisory Board
Heikki Lanckriet Member-Supervisory Board
Helge Lubenow Member-Supervisory Board
Karlheinz Schmelig Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA AG-28.38%64
CSL LIMITED-5.75%93 171
SAMSUNG BIOLOGICS CO.,LTD.-10.52%44 721
BIOGEN INC.-19.52%28 278
WUXI BIOLOGICS (CAYMAN) INC.-43.60%28 063
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.71%21 889